AXL, along with PROS1, is overexpressed in papillary thyroid carcinoma and regulates its biological behaviour
出版年份 2022 全文链接
标题
AXL, along with PROS1, is overexpressed in papillary thyroid carcinoma and regulates its biological behaviour
作者
关键词
-
出版物
World Journal of Surgical Oncology
Volume 20, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-10-06
DOI
10.1186/s12957-022-02801-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer
- (2021) Yu-Ling Lu et al. Cancers
- Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway
- (2020) Xiangrui Meng et al. Frontiers in Oncology
- AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer
- (2019) Francesca Collina et al. Cancers
- Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2019) S Filetti et al. ANNALS OF ONCOLOGY
- TAM receptors, Phosphatidylserine, inflammation, and Cancer
- (2019) Tal Burstyn-Cohen et al. Cell Communication and Signaling
- Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma
- (2018) Hirokazu Sadahiro et al. CANCER RESEARCH
- Follow-up of differentiated thyroid cancer – what should (and what should not) be done
- (2018) Livia Lamartina et al. Nature Reviews Endocrinology
- Evolving Understanding of the Epidemiology of Thyroid Cancer
- (2018) Carolyn Dacey Seib et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- TAM receptor signaling in development
- (2017) Tal Burstyn-Cohen INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY
- Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
- (2017) Masamichi Mori et al. INVESTIGATIONAL NEW DRUGS
- The autophagy marker LC3 strongly predicts immediate mortality after surgical resection for hepatocellular carcinoma
- (2017) Chih-Wen Lin et al. Oncotarget
- Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL
- (2017) Ghada Abboud-Jarrous et al. Oncotarget
- Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin
- (2017) Manoj Garg et al. Scientific Reports
- Role of protein S in castration-resistant prostate cancer-like cells
- (2016) Peng Ning et al. ENDOCRINE-RELATED CANCER
- Clinicopathological features of recurrent papillary thyroid cancer
- (2015) Jian Zhu et al. Diagnostic Pathology
- Cabozantinib in Thyroid Cancer
- (2015) Poupak Fallahi et al. Recent Patents on Anti-Cancer Drug Discovery
- Current Thyroid Cancer Trends in the United States
- (2014) Louise Davies et al. JAMA Otolaryngology-Head & Neck Surgery
- Axl is essential for VEGF-A-dependent activation of PI3K/Akt
- (2012) Guo-Xiang Ruan et al. EMBO JOURNAL
- The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target
- (2012) J D Paccez et al. ONCOGENE
- Epithelial cell-directed efferocytosis in the post-partum mammary gland is necessary for tissue homeostasis and future lactation
- (2011) Melissa Sandahl et al. BMC DEVELOPMENTAL BIOLOGY
- The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma
- (2011) Alvarez Hector et al. CANCER BIOLOGY & THERAPY
- Activation of TYRO3/AXL Tyrosine Kinase Receptors in Thyroid Cancer
- (2011) E. Avilla et al. CANCER RESEARCH
- R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer
- (2010) S. J. Holland et al. CANCER RESEARCH
- Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis
- (2009) Y Li et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now